-
公开(公告)号:US08318132B2
公开(公告)日:2012-11-27
申请号:US12372717
申请日:2009-02-17
申请人: Hartmuth C. Kolb , Joseph C. Walsh , Wei Zhang , Peter J. H. Scott , Kai Chen , Vani P. Mocharla , Dhanalakshmi Kasi , Gang Chen , Eric Wang , Anjana Sinha
发明人: Hartmuth C. Kolb , Joseph C. Walsh , Wei Zhang , Peter J. H. Scott , Kai Chen , Vani P. Mocharla , Dhanalakshmi Kasi , Gang Chen , Eric Wang , Anjana Sinha
CPC分类号: C07B59/002
摘要: Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled flavones, coumarins, carbazoles, quinolinones, chromenones, imidazoles and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease.
摘要翻译: 本文公开了在哺乳动物中诊断阿尔茨海默病或其倾向的化合物和方法,所述方法包括向哺乳动物施用诊断有效量的放射性标记的化合物,其中所述化合物选自放射性标记的黄酮,香豆素,咔唑 ,喹啉酮,色烯酮,咪唑和三唑衍生物,使化合物分布到脑组织中,并使脑组织成像,其中与正常对照结合水平相比,化合物与脑组织的结合增加指示哺乳动物 患有或有发生阿尔茨海默病的风险。
-
公开(公告)号:US08420052B2
公开(公告)日:2013-04-16
申请号:US12509259
申请日:2009-07-24
申请人: Hartmuth C. Kolb , Joseph C. Walsh , Wei Zhang , Umesh B. Gangadharmath , Dhanalakshmi Kasi , Kai Chen , Anjana Sinha , Eric Wang , Gang Chen , Peter J. H. Scott , Henry Clifton Padgett , Qianwa Liang , Zhiyong Gao , Tieming Zhao , Chunfang Xia , Vani P. Mocharla
发明人: Hartmuth C. Kolb , Joseph C. Walsh , Wei Zhang , Umesh B. Gangadharmath , Dhanalakshmi Kasi , Kai Chen , Anjana Sinha , Eric Wang , Gang Chen , Peter J. H. Scott , Henry Clifton Padgett , Qianwa Liang , Zhiyong Gao , Tieming Zhao , Chunfang Xia , Vani P. Mocharla
CPC分类号: C07D417/14 , A61K51/0406 , A61K51/0453 , A61K51/0455 , A61K51/0459 , C07D277/64 , C07D277/68 , C07D417/04 , C07D471/04 , C07D498/14 , C07D513/04 , C07D513/14
摘要: Provided herein are compounds and compositions which comprise the formulae as disclosed herein, wherein the compound is an amyloid binding compound. An amyloid binding compound according to the invention may be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits, and distinguish between neurological tissue with amyloid deposits and normal neurological tissue. Amyloid probes of the invention may be used to detect and quantitate amyloid deposits in diseases including, for example, Down's syndrome, familial Alzheimer's Disease. In another embodiment, the compounds may be used in the treatment or prophylaxis of neurodegenerative disorders. Also provided herein are methods of allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing a neurodegenerative disease.
摘要翻译: 本文提供了包含本文公开的式的化合物和组合物,其中所述化合物是淀粉样蛋白结合化合物。 根据本发明的淀粉样蛋白结合化合物可以以适于淀粉样蛋白沉积物的体内成像的量施用于患者,并且可以区分具有淀粉样沉积物的神经组织和正常神经组织。 本发明的淀粉样蛋白探针可用于检测和定量疾病中的淀粉样蛋白沉积物,包括例如唐氏综合症,家族性阿尔茨海默氏病。 在另一个实施方案中,所述化合物可用于治疗或预防神经变性疾病。 本文还提供了允许化合物分布到脑组织中并对脑组织成像的方法,其中与正常对照结合水平相比,化合物与脑组织的结合增加指示哺乳动物患有或 有发展神经变性疾病的风险。
-
公开(公告)号:US20120302755A1
公开(公告)日:2012-11-29
申请号:US13477095
申请日:2012-05-22
申请人: Anna Katrin Szardenings , Hartmuth C. Kolb , Joseph C. Walsh , Gang Chen , Umesh B. Gangadharmath , Dhanalakshmi Kasi , Changhui Liu , Anjana Sinha , Eric Wang , Chul Yu , Wei Zhang , Kai Chen , Vani P. Mocharla , Peter J.H. Scott
发明人: Anna Katrin Szardenings , Hartmuth C. Kolb , Joseph C. Walsh , Gang Chen , Umesh B. Gangadharmath , Dhanalakshmi Kasi , Changhui Liu , Anjana Sinha , Eric Wang , Chul Yu , Wei Zhang , Kai Chen , Vani P. Mocharla , Peter J.H. Scott
IPC分类号: C07D471/04 , C07D471/14
CPC分类号: A61K51/0455 , A61K51/0446 , C07B59/002 , C07D471/04 , C07D471/14
摘要: Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled carbazoles and derivatives thereof and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease.
摘要翻译: 本文公开了在哺乳动物中诊断阿尔茨海默病或倾向于其的化合物和方法,所述方法包括向哺乳动物施用诊断有效量的放射性标记的化合物,其中所述化合物选自放射性标记的咔唑及其衍生物,以及 三唑衍生物,允许化合物分布到脑组织中并对脑组织进行成像,其中与正常对照水平的结合相比,化合物与脑组织的结合增加表明哺乳动物患有或处于危险中 发展为阿尔茨海默病。
-
公开(公告)号:US20110046378A1
公开(公告)日:2011-02-24
申请号:US12867502
申请日:2009-02-17
申请人: Hartmuth C. Kolb , Joseph C. Walsh , Qianwa Liang , Brian A. Duclos , Wei Zhang , Peter J.H. Scott , Kai Chen , Zhiyong Gao , Tieming Zhao , Vani P. Mocharla , Dhanalakshmi Kasi , Gang Chen , Eric Wang , Anjana Sinha , Chunfang Xia , Henry Clifton Padgett , Farhad Karimi
发明人: Hartmuth C. Kolb , Joseph C. Walsh , Qianwa Liang , Brian A. Duclos , Wei Zhang , Peter J.H. Scott , Kai Chen , Zhiyong Gao , Tieming Zhao , Vani P. Mocharla , Dhanalakshmi Kasi , Gang Chen , Eric Wang , Anjana Sinha , Chunfang Xia , Henry Clifton Padgett , Farhad Karimi
IPC分类号: C07D471/04 , C07D235/10 , C07D311/30 , C07D209/88 , C07D311/16 , C07D217/24 , C07D261/08 , C07D217/04 , C07D215/38 , C07D405/04 , C07D215/233 , C07D407/04 , C07D249/06 , C07D401/04 , C07D209/80 , C07D405/12
CPC分类号: C07B59/002
摘要: Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled flavones, coumarins, carbazoles, quinolinones, chromenones, imidazoles and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease
摘要翻译: 本文公开了在哺乳动物中诊断阿尔茨海默病或其倾向的化合物和方法,所述方法包括向哺乳动物施用诊断有效量的放射性标记的化合物,其中所述化合物选自放射性标记的黄酮,香豆素,咔唑 ,喹啉酮,色烯酮,咪唑和三唑衍生物,使化合物分布到脑组织中,并使脑组织成像,其中与正常对照结合水平相比,化合物与脑组织的结合增加指示哺乳动物 患有或有发生阿尔茨海默病的风险
-
公开(公告)号:US20110091382A1
公开(公告)日:2011-04-21
申请号:US12372717
申请日:2009-02-17
申请人: Hartmuth C. Kolb , Joseph C. Walsh , Qianwa Liang , Brian A. Duclos , Wei Zhang , Peter J.H. Scott , Kai Chen , Zhiyong Gao , Tieming Zhao , Vani P. Mocharla , Dhanalakshmi Kasi , Gang Chen , Eric Wang , Anjana Sinha , Chunfang Xia , Henry Clifton Padgett , Farhad Karimi
发明人: Hartmuth C. Kolb , Joseph C. Walsh , Qianwa Liang , Brian A. Duclos , Wei Zhang , Peter J.H. Scott , Kai Chen , Zhiyong Gao , Tieming Zhao , Vani P. Mocharla , Dhanalakshmi Kasi , Gang Chen , Eric Wang , Anjana Sinha , Chunfang Xia , Henry Clifton Padgett , Farhad Karimi
IPC分类号: A61K51/04 , C07D209/82 , C07D311/20 , C07D403/12 , C07D405/12 , C07D471/04 , A61P25/28 , A61P25/00 , A61P25/22 , A61P25/24 , A61P25/18
CPC分类号: C07B59/002
摘要: Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled flavones, coumarins, carbazoles, quinolinones, chromenones, imidazoles and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease.
摘要翻译: 本文公开了在哺乳动物中诊断阿尔茨海默病或其倾向的化合物和方法,所述方法包括向哺乳动物施用诊断有效量的放射性标记的化合物,其中所述化合物选自放射性标记的黄酮,香豆素,咔唑 ,喹啉酮,色烯酮,咪唑和三唑衍生物,使化合物分布到脑组织中,并使脑组织成像,其中与正常对照结合水平相比,化合物与脑组织的结合增加指示哺乳动物 患有或有发生阿尔茨海默病的风险。
-
公开(公告)号:US20160304555A1
公开(公告)日:2016-10-20
申请号:US14917127
申请日:2012-08-21
申请人: Eric WANG , Hartmuth C. KOLB , Anna Katrin INGS , Changhui LIU , Joseph C. WALSH , Gang CHEN , Anjana SINHA , Dhanalakshmi KASI , Chul YU , Umesh B. GANGADHARMATH , Wei ZHANG , Tieming ZHAO , Vani P. MOCHARLA
发明人: Eric Wang , Hartmuth C. Kolb , Anna Katrin Szardenings , Changhui Liu , Joseph C. Walsh , Gang Chen , Anjana Sinha , Dhanalakshmi Kasi , Chul Yu , Umesh B. Gangadharmath , Wei Zhang , Tieming Zhao , Vani P. Mocharla
IPC分类号: C07K5/02 , A61K51/04 , A61K51/08 , C07D249/06 , C07D249/04
CPC分类号: C07K5/0215 , A61K38/00 , A61K51/0453 , A61K51/088 , C07D207/16 , C07D209/48 , C07D213/81 , C07D213/82 , C07D233/78 , C07D233/96 , C07D239/60 , C07D249/04 , C07D249/06 , C07D251/30 , C07D263/34 , C07D277/56 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/12 , C07K5/06026 , C07K5/06113
摘要: Compounds for targeting and agents for imaging, Prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.
摘要翻译: 公开了靶向化合物和成像剂,前列腺特异性膜抗原(PSMA)。 还公开了合成化合物和成像剂的方法以及PSMA成像方法。 所公开的成像剂适用于PET和SPECT成像。
-
公开(公告)号:US10011632B2
公开(公告)日:2018-07-03
申请号:US14917127
申请日:2012-08-21
申请人: Eric Wang , Hartmuth C. Kolb , Anna Katrin Szardenings , Changhui Liu , Joseph C. Walsh , Gang Chen , Anjana Sinha , Dhanalakshmi Kasi , Chul Yu , Umesh B. Gangadharmath , Wei Zhang , Tieming Zhao , Vani P. Mocharla
发明人: Eric Wang , Hartmuth C. Kolb , Anna Katrin Szardenings , Changhui Liu , Joseph C. Walsh , Gang Chen , Anjana Sinha , Dhanalakshmi Kasi , Chul Yu , Umesh B. Gangadharmath , Wei Zhang , Tieming Zhao , Vani P. Mocharla
IPC分类号: C07K5/02 , A61K51/04 , C07D249/06 , C07D249/04 , A61K51/08 , C07K5/062 , C07K5/072 , C07D403/12 , C07D213/81 , C07D213/82 , C07D233/78 , C07D233/96 , C07D401/12 , C07D403/06 , C07D405/12 , C07D239/60 , C07D251/30 , C07D263/34 , C07D207/16 , C07D277/56 , C07D209/48 , A61K38/00
CPC分类号: C07K5/0215 , A61K38/00 , A61K51/0402 , A61K51/0453 , A61K51/0497 , A61K51/088 , C07D207/16 , C07D209/48 , C07D213/81 , C07D213/82 , C07D233/78 , C07D233/96 , C07D239/60 , C07D249/04 , C07D249/06 , C07D251/30 , C07D263/34 , C07D277/56 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/12 , C07K5/06026 , C07K5/06113
摘要: Compounds for targeting and agents for imaging, Prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.
-
公开(公告)号:US08491869B2
公开(公告)日:2013-07-23
申请号:US12661777
申请日:2010-03-23
申请人: Umesh B. Gangadharmath , Hartmuth C. Kolb , Peter J. H. Scott , Joseph C. Walsh , Wei Zhang , Anna Katrin Szardenings , Anjana Sinha , Gang Chen , Eric Wang , Vani P. Mocharia , Chul Yu , Changhui Liu , Daniel Kurt Cashion , Dhanalakshmi Kasi
发明人: Umesh B. Gangadharmath , Hartmuth C. Kolb , Peter J. H. Scott , Joseph C. Walsh , Wei Zhang , Anna Katrin Szardenings , Anjana Sinha , Gang Chen , Eric Wang , Vani P. Mocharia , Chul Yu , Changhui Liu , Daniel Kurt Cashion , Dhanalakshmi Kasi
CPC分类号: A61K51/0455 , A61K51/04 , A61K51/0453 , A61K51/0459 , A61K51/0463 , C07B59/002 , C07D215/06 , C07D235/14 , C07D277/62 , C07D401/04 , C07D403/06 , C07D413/10 , C07D413/14 , C07D487/04
摘要: Imaging agents of formula (I) and methods for detecting neurological disorders comprising administering ti a patient in need compounds of formula (I) capable of binding to tau proteins and β-amyloid peptides are presented herein. The invention also relates to methods of imaging Aβ and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formula (I) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disorders.
摘要翻译: 式(I)的成像剂和用于检测神经障碍的方法包括给予需要能够结合tau蛋白和β-淀粉样肽的式(I)化合物的化合物。 本发明还涉及成像Abeta和tau聚集体的方法,包括引入可检测量的包含放射性标记的式(I)化合物的药物制剂,并检测患者中与淀粉样蛋白沉积物和/或tau蛋白相关的标记化合物。 这些方法和组合使得临床前诊断和监测AD和其他神经障碍的进展。
-
公开(公告)号:US20100098634A1
公开(公告)日:2010-04-22
申请号:US12509259
申请日:2009-07-24
申请人: Hartmuth C. Kolb , Joseph C. Walsh , Wei Zhang , Umesh B. Gangadharmath , Dhanalakshmi Kasi , Kai Chen , Anjana Sinha , Eric Wang , Gang Chen , Peter J.H. Scott , Henry Clifton Padgett , Qianwa Liang , Zhiyong Gao , Tieming Zhao , Chunfang Xia
发明人: Hartmuth C. Kolb , Joseph C. Walsh , Wei Zhang , Umesh B. Gangadharmath , Dhanalakshmi Kasi , Kai Chen , Anjana Sinha , Eric Wang , Gang Chen , Peter J.H. Scott , Henry Clifton Padgett , Qianwa Liang , Zhiyong Gao , Tieming Zhao , Chunfang Xia
IPC分类号: A61K51/04 , C07D277/02 , C07D495/02 , C07D209/34 , C07D221/02 , C07D455/00 , C07D417/00 , C07D487/00 , C07D401/02 , C07D471/00 , C07D209/82 , C07D307/91 , A61P25/28 , G01N33/53
CPC分类号: C07D417/14 , A61K51/0406 , A61K51/0453 , A61K51/0455 , A61K51/0459 , C07D277/64 , C07D277/68 , C07D417/04 , C07D471/04 , C07D498/14 , C07D513/04 , C07D513/14
摘要: Provided herein are compounds and compositions which comprise the formulae as disclosed herein, wherein the compound is an amyloid binding compound. An amyloid binding compound according to the invention may be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits, and distinguish between neurological tissue with amyloid deposits and normal neurological tissue. Amyloid probes of the invention may be used to detect and quantitate amyloid deposits in diseases including, for example, Down's syndrome, familial Alzheimer's Disease. In another embodiment, the compounds may be used in the treatment or prophylaxis of neurodegenerative disorders. Also provided herein are methods of allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing a neurodegenerative disease.
摘要翻译: 本文提供了包含本文公开的式的化合物和组合物,其中所述化合物是淀粉样蛋白结合化合物。 根据本发明的淀粉样蛋白结合化合物可以以适于淀粉样蛋白沉积物的体内成像的量施用于患者,并且可以区分具有淀粉样沉积物的神经组织和正常神经组织。 本发明的淀粉样蛋白探针可用于检测和定量疾病中的淀粉样蛋白沉积物,包括例如唐氏综合症,家族性阿尔茨海默氏病。 在另一个实施方案中,所述化合物可用于治疗或预防神经变性疾病。 本文还提供了允许化合物分布到脑组织中并对脑组织成像的方法,其中与正常对照结合水平相比,化合物与脑组织的结合增加指示哺乳动物患有或 有发展神经变性疾病的风险。
-
公开(公告)号:US20110182812A1
公开(公告)日:2011-07-28
申请号:US13035405
申请日:2011-02-25
申请人: Anna Katrin Szardenings , Wei Zhang , Hartmuth C. Kolb , Daniel Kurt Cashion , Gang Chen , Dhanalakshmi Kasi , Changhui Liu , Anjana Sinha , Eric Wang , Chul Yu , Umesh B. Gangadharmath , Joseph C. Walsh
发明人: Anna Katrin Szardenings , Wei Zhang , Hartmuth C. Kolb , Daniel Kurt Cashion , Gang Chen , Dhanalakshmi Kasi , Changhui Liu , Anjana Sinha , Eric Wang , Chul Yu , Umesh B. Gangadharmath , Joseph C. Walsh
IPC分类号: A61K51/04 , C07D513/04 , C07D231/56 , C07D487/04 , C07D471/04 , C07D413/14 , C07D401/10 , C07D401/04 , A61K49/00 , A61P43/00 , A61P25/28
CPC分类号: C07D235/04 , A61K51/04 , C07B59/002 , C07D215/06 , C07D235/14 , C07D277/62 , C07D401/02 , C07D401/04 , C07D403/06 , C07D413/10 , C07D413/14 , C07D471/04 , C07D487/04
摘要: Imaging agents of formulas (I)-(V) and methods for detecting neurological disorders comprising administering to a patient in need compounds of formulas (I)-(V) capable of binding to tau proteins and β-amyloid peptides are presented herein. The invention also relates to methods of imaging Aβ and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formulas (I)-(V) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disorders.
摘要翻译: 式(I) - (V)的成像剂和用于检测神经障碍的方法包括向需要的患者施用能够结合tau蛋白和&淀粉样蛋白肽的式(I) - (V)化合物。 本发明还涉及成像A&bgr的方法; 和tau聚集体,其包括引入可检测量的包含放射性标记的式(I) - (V)化合物的药物制剂,并检测患者中与淀粉样蛋白沉积物和/或tau蛋白相关的标记化合物。 这些方法和组合使得临床前诊断和监测AD和其他神经障碍的进展。
-
-
-
-
-
-
-
-
-